Biogen Idec Loses Another Board Member
This article was originally published in The Pink Sheet Daily
Lame duck R&D chief Pickett will also give up directorship, boosting Carl Icahn's percentage of seats - for now.
You may also be interested in...
After a drama-packed shareholder meeting on June 3, Carl Icahn claims he won two of four contested seats on the 13-person, Biogen Idec board
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
With an unrestricted label and once-daily dosing, rivaroxaban will do battle with Boehringer-Ingelheim's dabigatran, which is dosed twice a day but can claim superior efficacy to warfarin in the atrial fibrillation population.